Apogee Therapeutics (APGE) Capital Expenditures (2024 - 2026)
Apogee Therapeutics (APGE) posted quarterly Capital Expenditures of -$155000.0 for Q1 2026, down 102.27% year-over-year from $6.8 million in Q1 2025, and up 95.43% quarter-over-quarter from -$3.4 million in Q4 2025.
Apogee Therapeutics (APGE) Capital Expenditures (2024 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Capital Expenditures for 3 consecutive years, with -$155000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 102.27% year-over-year to -$155000.0; the TTM figure through Mar 2026 stood at -$1.8 million (down 124.2% YoY), while the FY2025 annual figure was $5.1 million, up 346.79% from the prior year.
- Capital Expenditures climbed to -$155000.0 in Q1 2026 per APGE's latest filing, from -$3.4 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $6.8 million in Q1 2025 and bottomed at -$3.4 million in Q4 2025.
- Historically, Capital Expenditures has averaged $682666.7 across 3 years, with a median of $51000.0 in 2024.
- On a YoY basis, Capital Expenditures climbed as much as 1849.0% in 2025 and fell as far as 339200.0% in 2025.
- Apogee Therapeutics' Capital Expenditures stood at -$1000.0 in 2024, then slumped by 339200.0% to -$3.4 million in 2025, then jumped by 95.43% to -$155000.0 in 2026.
- Business Quant data shows APGE's Capital Expenditures at -$155000.0 in Q1 2026, -$3.4 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | 2.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.09 Mn |
| Jun 30, 2026 | 2.09 Mn |
| Mar 31, 2026 | -155,000.00 |
| Mar 31, 2026 | -155,000.00 |
| Dec 31, 2025 | -3.39 Mn |
| Dec 31, 2025 | -3.39 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Jun 30, 2025 | -1.76 Mn |
| Jun 30, 2025 | -1.76 Mn |
| Mar 31, 2025 | 6.84 Mn |
| Mar 31, 2025 | 6.84 Mn |
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 751,000.00 |
| Sep 30, 2024 | 751,000.00 |
| Jun 30, 2024 | 51,000.00 |
| Jun 30, 2024 | 51,000.00 |
| Mar 31, 2024 | 351,000.00 |
| Mar 31, 2024 | 351,000.00 |